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Purpose: The purpose of the current study was threefold: (a) investigate the impact
of the variations (errors) in spot sizes in robustly optimized pencil beam scanning
(PBS) proton-based stereotactic body radiation therapy (SBRT) lung plans, (b) evalu-
ate the impact of spot sizes and position errors simultaneously, and (c) assess the
overall effect of spot size and position errors occurring simultaneously in conjunc-
tion with either setup or range errors.
Methods: In this retrospective study, computed tomography (CT) data set of five
lung patients was selected. Treatment plans were regenerated for a total dose of
5000 cGy(RBE) in 5 fractions using a single-field optimization (SFO) technique.
Monte Carlo was used for the plan optimization and final dose calculations. Nominal
plans were normalized such that 99% of the clinical target volume (CTV) received
the prescription dose. The analysis was divided into three groups. Group 1: The
increasing and decreasing spot sizes were evaluated for 10%, 15%, and 20%
errors. Group 2: Errors in spot size and spot positions were evaluated simultaneously
(spot size: 10%; spot position: 1 and 2 mm). Group 3: Simulated plans from
Group 2 were evaluated for the setup (5 mm) and range (3.5%) errors.
Results: Group 1: For the spot size errors of 10%, the average reduction in D99%
for −10% and +10% errors was 0.7% and 1.1%, respectively. For −15% and +15%
spot size errors, the average reduction in D99% was 1.4% and 1.9%, respectively.
The average reduction in D99% was 2.1% for −20% error and 2.8% for +20% error.
The hot spot evaluation showed that, for the same magnitude of error, the decreas-
ing spot sizes resulted in a positive difference (hotter plan) when compared with the
increasing spot sizes. Group 2: For a 10% increase in spot size in conjunction with a
−1 mm (+1 mm) shift in spot position, the average reduction in D99% was 1.5%
(1.8%). For a 10% decrease in spot size in conjunction with a −1 mm (+1 mm) shift
in spot position, the reduction in D99% was 0.8% (0.9%). For the spot size errors of
10% and spot position errors of 2 mm, the average reduction in D99% was 2.4%.
Group 3: Based on the results from 160 plans (4 plans for spot size [10%] and
position [1 mm] errors × 8 scenarios × 5 patients), the average D99% was
4748 cGy(RBE) with the average reduction of 5.0%. The isocentric shift in the
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superior–inferior direction yielded the least homogenous dose distributions inside
the target volume.
Conclusion: The increasing spot sizes resulted in decreased target coverage and
dose homogeneity. Similarly, the decreasing spot sizes led to a loss of target cover-
age, overdosage, and degradation of dose homogeneity. The addition of spot size
and position errors to plan robustness parameters (setup and range uncertainties)
increased the target coverage loss and decreased the dose homogeneity.
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1 | INTRODUCTION
In pencil beam scanning (PBS) proton delivery, the accuracy of the
size and position of a pencil proton beam is very critical to minimize
the discrepancies between the delivered and computed doses. Spot
sizes on the proton beam delivery system can be affected by the
fluctuations in the beam extraction and transport systems.1 Addition-
ally, the presence of different scattering materials in the nozzle,1 as
well as the air gap between the range shifter and patient, can have
an impact on the spot size.2 Similarly, the positioning of the spots
can be affected by the fluctuations in the steering magnetic fields.3,4
Hence, the variations in the delivered spot sizes and positions could
lead to perturbation of dose distributions impacting the quality of
the treatment plan delivered to the patient.1–7
In order to minimize the discrepancies between the computed
and delivered dose distributions in PBS proton therapy, tolerance
levels are proposed for the spot size and position errors. Parodi
et al.1 evaluated the impact of spot size on spherical phantom plans
and proposed the tolerance of 50%. Chanrion et al.5 studied the
variations in spot sizes on prostate and skull-base patients and
reported negligible to moderate changes in dose distributions when
spot sizes are changed by ⩽25%. Lin et al.8 performed a study on
28 patients of different disease sites (breast, sarcoma, central ner-
vous system, pediatric, gastrointestinal, genitourinary, and gyneco-
logical). Based on their gamma analysis, the spot size tolerance of
10% was proposed.8 Kraan and colleagues7 demonstrated that the
variation in spot size is patient and spot width dependent. Their
study7 included seven patients of different disease sites (pelvis,
chest wall, rectum, chordoma, cardiac, retro-peritoneal, and sarcoma)
and a phantom. If in-air one sigma (σ) of a pencil beam is 2.5 mm,
the tolerance is 25%.7 Similarly, for σ of 5 and 10 mm, the pro-
posed tolerances are 25% and 10%, respectively.7 For the spot
position errors, the tolerance of 1 mm has been reported by the
investigators.4,8–10 Recently, the AAPM TG224 report11 recom-
mended the tolerance of 10% for the spot size and 1 mm for
the spot position.
Previous publications1-9 have reported the variations in spot size
and position in the phantoms and disease sites but not for the lung. For
PBS lung cancer treatment, the accuracy of the dose calculation algo-
rithm in predicting spot size and dose distributions becomes more criti-
cal due to varying tissue densities in the proton beam path. In
commercial proton treatment planning systems (TPS), Monte Carlo algo-
rithms have been shown to be more accurate in estimating spot sizes
than analytical pencil beam algorithms.12,13 A growing number of publi-
cations14–17 have now recommended using the Monte Carlo algorithm
for the dose calculations in PBS lung cancer. Recently, robust optimiza-
tion14,18 feature has been made available in the clinical environment,
whereas previous studies1,5-8 did not address the impact of variation in
spot size on robustly optimized clinical plans. It is essential to under-
stand the effects of errors in spot sizes on the Monte Carlo algorithm-
based robustly optimized PBS lung cancer plans. Additionally, none of
the previous studies1–9 have studied the impact of the errors in spot
sizes and positions simultaneously. In the current study, we aim to
answer the following questions regarding the robustly optimized PBS
proton-based stereotactic body radiation therapy (SBRT) lung plans:
1. What is the dosimetric impact of spot size errors of 10%,
15%, and 20%?
2. What is the dosimetric impact of spot size and position errors
occurring simultaneously? The simultaneous evaluation is per-
formed by combining spot size and position errors (spot size:
10% and spot position: 1 and 2 mm)?
3. What are the overall effect of spot size (10%) and position
(1 mm) errors in conjunction with either setup (5 mm) or
range (3.5%) errors?
2 | MATERIALS AND METHODS
2.A | Contouring and treatment planning
In this retrospective study, PBS lung plans were replanned on the
computed tomography (CT) data set of five lung patients. The
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clinical target volume (CTV) ranged from 24.27 to 63.24 cc. The
CTV was created by an isotropic margin of 5 mm around
the internal gross tumor volume (IGTV). The IGTV was obtained
based on the four-dimensional computed tomography (4DCT)
images. For proton planning, the average intensity projection CT
was utilized.
RayStation TPS (Version 9B; RaySearch Laboratories, Stockholm,
Sweden) was used for treatment planning. The proton beam model
is based on the IBA ProteusPLUS proton therapy system with a
PBS dedicated nozzle (Ion Beam Applications, Louvain-la-Neuve,
Belgium).19,20 The in-air one sigma (σ) for 226.5 MeV at the isocen-
ter is ~3 mm.19 For each patient, a nominal plan was regenerated
for a total dose of 5000 cGy(RBE) in 5 fractions using an average
RBE of 1.1. Treatment plans were robustly optimized using a
single-field optimization (SFO) technique. The Monte Carlo algo-
rithm (10 000 ions/spot) was utilized for the robust optimization.
The robustness (range uncertainty = 3.5% and setup error =
5 mm) was applied on the CTV such that its 99% of the relative
volume receives at least the prescription dose (5000 cGy(RBE)).
Based on the input values of robustness parameters, RayStation
optimized each plan for a total of 21 scenarios. The final dose cal-
culations were performed using the Monte Carlo (grid size: 2 mm;
statistical uncertainty = 0.5%). This was followed by the creation of
a volumetric repainting plan with five paintings in an alternating
order.21,22 The resulting plan was then normalized such that the
CTV D99% = 5000 cGy(RBE). The final nominal plan was denoted
as D(0%, 0 mm), which means 0% error in spot size and 0-mm
error in spot position.
2.B | Spot size errors simulation
In order to simulate the spot size errors of 10%, 15%, and 20%,
additional six beam models were generated. These were simulated
by scaling the spot profiles in the nominal beam model. In the simu-
lated beam models, absolute dose output and integrated depth doses
(IDDs) remained identical as in the nominal beam model.
2.C | Dose calculations for spot size errors only
The spot size errors calculation was performed by recomputing D
(0%, 0 mm) plan using the simulated beam models (10%, 15%,
and 20%). For instance, if D(0%, 0 mm) plan was recomputed for
the spot size error of +10% and spot position error of 0 mm, the
resulting plan was denoted as D(+10%, 0 mm). Similarly, for −20%
spot size and 0-mm spot position errors, the plan was denoted as
D(−20%, 0 mm). Dose recomputations were performed using the
Monte Carlo algorithm without plan reoptimization.
2.D | Spot position errors simulation
The D(0%, 0 mm) plan containing the spot position information was
exported from the TPS to a local computer. Then spot positions in
the treatment plan were varied systematically by −1 and +1 mm,
thus resulting in two simulated plans, D(0%, −1 mm) and D(0%,
+1 mm), respectively. This process was repeated for the systematic
shift of spot positions by 2 mm to generate D(0%, −2 mm) and D
(0%, +2 mm) plans. The simulation of spot position errors was per-
formed using an in-house developed MatLab code (Version R2019b;
MathWorks, Natick, MA, USA).
2.E | Dose calculation for the spot size and position
errors occurring simultaneously
For each patient, simulated plans for spot positions (as described in
Section 2D) were imported back into RayStation TPS. The D(0%,
−1 mm) plan was recomputed using Monte Carlo algorithm (without
reoptimization) for the spot size errors of −10% and +10%, resulting
in D(−10%, −1 mm) and D(+10%, −1 mm) plans, respectively. The D
(0%, +1 mm) plan was recomputed using Monte Carlo algorithm
(without reoptimization) for the spot size errors of −10% and +10%,
resulting in D(−10%, +1 mm) and D(+10%, +1 mm) plans, respec-
tively. Similarly, the D(0%, −2 mm) and D(0%, +2 mm) plans were
recomputed using Monte Carlo algorithm (without reoptimization)
for 10% spot size errors.
2.F | Robustness
The D(10%, 1 mm) plans were evaluated for a total of eight sce-
narios. The setup uncertainty was simulated by a 5-mm isocenter
shift in the left–right, superior–inferior, and anterior–posterior direc-
tions of the patient resulting in six scenarios. The range uncertainty
was evaluated for two scenarios (3.5%).
2.G | Analysis
The analysis was divided into three groups. The first group (Group 1)
consisted of plans simulated for spot size errors only, as described in
Section 2.C. The second group (Group 2) included the plans that
were simulated for spot size and position errors occurring simultane-
ously. The simulated plans in the Group 2 are described in Sec-
tion 2.E. Finally, the third group (Group 3) included the evaluation of
D(10%, 1 mm) plans for setup (5 mm) and range (3.5%) uncer-
tainties as described in Section 2.F.
The difference (Δ) at a dosimetric metric (e.g., D99%) between






DNominalx% = result for x metric (e.g., 99) in the nominal plan.
DSimulatedx% = result for x metric in a simulated plan.




The CTV dose homogeneity index (HI) was evaluated using Eq.
(3), as shown below:
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F I G . 1 . The average difference in clinical target volume D95% (left panel) and D99% (right panel) between simulated plans in Group 1 and
nominal plans for the spot size errors (10%, 15%, and 20%). The results are averaged over all five patients.
F I G . 2 . Dose distributions in an example
patient: (a) nominal plan, (b) simulated plan
for the decreasing spot size (−10%) and
spot position (+1 mm) evaluated
simultaneously; (c) simulated plan for the
increasing spot size (+10%) and spot
position (+1 mm) evaluated simultaneously.
The loss of target coverage in the
simulated plans is shown by the red
arrows on the right panel.
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HI ¼ D1%D99%ð Þ
Rx
(3)
where Rx is the prescription dose (5000 cGy(RBE)). Based on Eq. (3),
the HI value of 0 is considered an ideal HI result.
3 | RESULTS
3.A | Group 1: Spot size errors
The spot size errors resulted in a loss of the target coverage (Fig. 1).
The reduction in target coverage increased as the magnitude of spot
size error was increased.
D95%: The Δavg. at D95% for −10% and +10% errors were −0.4%
and −0.6%, respectively. The Δavg. at D95% was −1.0% for 15%
errors. The Δavg. at D95% was −1.6% for 20% errors.
D99%: The Δavg. at D99% for −10% and +10% errors were −0.7%
and −1.1%, respectively. The Δavg. at D99% was −1.4% for −15%
error and −1.9% for +15% error. The Δavg. at D99% was −2.1% for
−20% error and −2.8% for +20% error.
HI: On average, the difference in HI results between nominal D(0%,
0 mm) and simulated plans for 10% errors (D(+10%, 0 mm) and D
(−10%, 0 mm)) was 0.01. For15% and20% spot size errors, decreas-
ing spot sizes resulted in less homogeneous plans compared with
increasing spot sizes. Specifically, for the spot size errors of 15%, it
was found that the average difference in HI was worse for D(−15%,
0 mm) plan (0.03) than D(+15%, 0 mm) plan (0.01) when their results
were compared against D(0%, 0 mm) plan. A similar trend was observed
for the spot size errors of 20%, with the average difference in HI being
worse for D(−20%, 0 mm) plan (0.04) than D(+20%, 0 mm) plan (0.02)
when their results were compared against D(0%, 0 mm) plan.
3.B | Group 2: Spot size and position errors
occurring simultaneously
Figure 2 illustrates the dose distributions in an example patient for
the nominal plan and simulated plan for the combined errors of the
decreasing (increasing) spot size −10% (+10%) and spot position
(+1 mm). Figure 3 shows the reduction in target coverage between
the nominal plan and simulated plan for the spot size errors (10%)
and spot position errors (1 mm). For a 10% increase in spot size
and 1-mm shift in spot position, the Δavg. at D99% was −1.5% for
D(+10%, −1 mm) plan and −1.8% for D(+10%, +1 mm) plan. For a
10% decrease in spot size and 1-mm shift in spot position, the
Δavg. at D99% was −0.8% for D(−10%, −1 mm) plan and −0.9% for D
(−10%, +1 mm) plan. Figure 3 also exhibits the results from D(10%,
2 mm) plans (n = 20) for the spot size errors of 10% and spot
position errors of 2 mm. For D(10%, 2 mm) plans, the Δavg. at
D99% was −2.4%.
3.C | Group 3: Setup and range errors
Figure 4 shows the results for simulated plans when setup (six sce-
narios) and range (two scenarios) errors are evaluated in conjunction
with spot size (10%) and position (1 mm) errors occurring simul-
taneously. The results are based on 160 plans (4 plans for spot size
[10%] and position [1 mm] errors × 8 scenarios × 5 patients).
F I G . 3 . The average difference in clinical target volume D99% between simulated plans in Group 2 and nominal plans for the spot size errors
(10%) in conjunction with spot position errors (1 and 2 mm). The results are averaged over all five patients.
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The average D99% was 4748 cGy(RBE), with an average reduction of
5.0%.
Figure 5 illustrates the difference in HI for various scenarios. The
worse HI result was obtained for a 5-mm isocenter shift in the supe-
rior–inferior directions (y =  5 mm). The average difference in HI
was 0.06.
4 | DISCUSSION
The current study was performed to investigate the dosimetric
impact of variations (errors) in the spot sizes and spot positions in
PBS proton-based SBRT lung plans. The results reported in the
current study complement previous findings1,5,7,8 by adding the
impact of variations in spot sizes and positions in robustly optimized
PBS lung plans. Due to the availability of the Monte Carlo algorithm
in commercially available TPS, researchers are recommending the
Monte Carlo algorithm for the optimization and dose calculations in
the proton lung plans.14–17 The current study provides additional
information regarding the impact of spot size and position errors on
the dose distributions of the lung plans, which were robustly opti-
mized (SFO technique) and calculated using the Monte Carlo algo-
rithm.
For a patient cohort in the current study, the variations in
spot sizes resulted in decreased target coverage and dose homo-
geneity. This was true for both the increasing and decreasing spot
F I G . 4 . (left panel) The average clinical target volume (CTV) D99% (left panel) from 120 plans of five patients from Group 3 analysis. (right
panel) The average difference in CTV D99% between simulated plans in Group 3 and nominal plans. The results are averaged over all five
patients.
F I G . 5 . (left panel) The difference in clinical target volume homogeneity index (HI) for eight different scenarios between simulated plans in
Group 3 and nominal plans. (right panel) Robustness parameters for eight scenarios of Group 3 analysis. The D(10%, 1 mm) plans are
evaluated for setup (5 mm) and range (3.5%) uncertainties as described in Section 2.F.
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sizes. For the spot size errors of 10%, the average loss of target
coverage was almost identical. Also, there was a minimum differ-
ence in the loss of target coverage between the increasing and
decreasing spot sizes for the 15% category. However, for the
spot size errors of 20%, it was found that the increasing spot
sizes resulted in a greater loss of target coverage at D99% when
compared with the decreasing spot sizes. The loss of target cover-
age due to the increasing and decreasing spot sizes can be attrib-
uted to the change in the lateral penumbra. The increase in spot
size led to the broadening of the lateral penumbra, whereas the
decrease in spot sizes led to the contraction of the lateral penum-
bra.5,7 The evaluation at D1% showed that, for the same magni-
tude of error, the average difference was higher (positive
difference) for the decreasing spot sizes than for the increasing
spot sizes. These findings suggest that the decreasing spot sizes
will also result in overdosage and loss dose homogeneity in the
target volume.
During proton beam delivery, there is a probability of variations
in both spot sizes and positions. Previous studies1–9 did not investi-
gate the variations in spot sizes and positions simultaneously but
rather focused either on the spot sizes or spot positions. According
to AAPM TG224, the recommended tolerances for the spot sizes
and spot positions are 10% and 1 mm, respectively. By simulat-
ing the errors in spot sizes (10%) and positions (1 mm) during
beam delivery, we quantified the loss of target coverage for a situ-
ation when both of these parameters could deviate from the
planned parameters. For the decreasing spot sizes (−10%) in con-
junction with 1-mm spot position errors, the target coverage was
reduced by up to 1.1% (at D99%). For the increasing spot sizes
(+10%) in conjunction with 1-mm spot position errors, the target
coverage was reduced by up to 2.5% (at D99%). If all the results of
10% spot size errors in conjunction with 1-mm spot position
errors are analyzed together, the average difference in the target
coverage at D99% was −1.3% (range, −0.5% to −2.5%) (Fig. 3). The
results from the combined effect of spot size and position errors
demonstrated the need for having stringent quality assurance (QA)
tolerances to avoid the loss of target coverage due to variations in
spot sizes and positions. It is important to note that clinical out-
comes can be correlated to the minimum dose to the delivered
tumor volume.23,24 In a more recent study, Sood et al.24 noted the
D99% as a potential predictive parameter for clinical outcome in
photon-based lung SBRT.
The majority of the proton centers evaluate the robustness of
PBS plans against the setup and range uncertainties,25 but there
appears to be no common consensus on the plan robustness criteria
in the proton therapy community. During PBS proton beam delivery,
there is a possibility of delivered spots deviating from their calcu-
lated sizes and positions. In the current study, we demonstrated
how the variations in spot sizes and positions could be combined
with either setup uncertainty or range uncertainty. By assuming the
spot size and position errors (10% and 1 mm, respectively) occur-
ring simultaneously in conjunction with setup errors, the D99% was
decreased by the average difference of 6.1%. Similarly, for the range
errors in conjunction with the spot size and spot position errors, we
noticed that the average decrease in D99% was by 2.0%. These
results suggest that the impact of setup errors was greater by three-
fold than the impact of range errors in robustly optimized PBS lung
plans when spot size and position errors are included in plan robust-
ness evaluation. The spot size and position errors in our study were
simulated systematically. During a real clinical scenario of proton
beam delivery, the deviations in spot size and position may not be
systematic. Future studies should investigate the impact of random
occurrence of spot size and position errors in PBS lung cancer plans.
5 | CONCLUSION
The increasing spot sizes resulted in decreased target coverage and
dose homogeneity. Similarly, the decreasing spot sizes led to a loss
of target coverage, overdosage, and degradation of dose homogene-
ity. The addition of spot size and position errors to plan robustness
parameters (setup and range uncertainties) increased the target cov-
erage loss and decreased the dose homogeneity.
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